Eef L Theunissen1, Annemiek Vermeeren, Johannes G Ramaekers. 1. Experimental Psychopharmacology Unit, Brain and Behaviour Institute, Faculty of Psychology, Maastricht University, the Netherlands. e.theunissen@psychology.unimaas.nl
Abstract
AIMS: Previous studies have demonstrated that the antihistaminesmequitazine, cetirizine and dexchlorpheniramine produce mild sedation after single doses. It is unknown, however, whether acute sedation persists after repeated dosing. Therefore, this study assessed the effects of repeated dosing of these antihistamines on driving and psychomotor performance. METHODS:Sixteen healthy volunteers were treated with mequitazine 10 mg q.a.m., cetirizine 10 mg q.a.m., dexchlorpheniramine Repetab 6 mg b.i.d. and placebo for four separate 8-day periods. Drug effects were assessed on days 1 and 8 using on-the-road driving tests (highway driving and car following), psychomotor tests (tracking and divided attention) and subjective questionnaires. RESULTS:Dexchlorpheniramine and mequitazine significantly impaired driving performance on the highway driving test on the first day; dexchlorpheniramine increased Standard Deviation of Lateral Position by 2 cm [95% confidence interval (CI) 0.5, 3.8] and mequitazine by 2.5 cm (CI 1.0, 4.3). These effects on driving performance disappeared after 8 days of treatment. No effect of treatment was found on car following, tracking and divided attention. Although subjective ratings confirmed that subjects knew their driving had been impaired in the mequitazine and dexchlorpheniramine condition after completion of the highway driving test on day 1, they did not expect their driving to be affected before the start of the test. Cetirizine did not impair performance on any of the tests. CONCLUSIONS: Single doses of mequitazine 10 mg and dexchlorpheniramine Repetab 6 mg cause mild driving impairment. However, when taken over several days, the impairing effect wears off, possibly as a result of tolerance.
RCT Entities:
AIMS: Previous studies have demonstrated that the antihistamines mequitazine, cetirizine and dexchlorpheniramine produce mild sedation after single doses. It is unknown, however, whether acute sedation persists after repeated dosing. Therefore, this study assessed the effects of repeated dosing of these antihistamines on driving and psychomotor performance. METHODS: Sixteen healthy volunteers were treated with mequitazine 10 mg q.a.m., cetirizine 10 mg q.a.m., dexchlorpheniramine Repetab 6 mg b.i.d. and placebo for four separate 8-day periods. Drug effects were assessed on days 1 and 8 using on-the-road driving tests (highway driving and car following), psychomotor tests (tracking and divided attention) and subjective questionnaires. RESULTS:Dexchlorpheniramine and mequitazine significantly impaired driving performance on the highway driving test on the first day; dexchlorpheniramine increased Standard Deviation of Lateral Position by 2 cm [95% confidence interval (CI) 0.5, 3.8] and mequitazine by 2.5 cm (CI 1.0, 4.3). These effects on driving performance disappeared after 8 days of treatment. No effect of treatment was found on car following, tracking and divided attention. Although subjective ratings confirmed that subjects knew their driving had been impaired in the mequitazine and dexchlorpheniramine condition after completion of the highway driving test on day 1, they did not expect their driving to be affected before the start of the test. Cetirizine did not impair performance on any of the tests. CONCLUSIONS: Single doses of mequitazine 10 mg and dexchlorpheniramine Repetab 6 mg cause mild driving impairment. However, when taken over several days, the impairing effect wears off, possibly as a result of tolerance.
Authors: Joris C Verster; A Marit de Weert; Saskia I R Bijtjes; Mounir Aarab; Armand W A A van Oosterwijck; Erik J E Eijken; Marinus N Verbaten; Edmund R Volkerts Journal: Psychopharmacology (Berl) Date: 2003-04-30 Impact factor: 4.530
Authors: Gary S Richardson; Timothy A Roehrs; Leon Rosenthal; Gail Koshorek; Thomas Roth Journal: J Clin Psychopharmacol Date: 2002-10 Impact factor: 3.153
Authors: N Okamura; K Yanai; M Higuchi; J Sakai; R Iwata; T Ido; H Sasaki; T Watanabe; M Itoh Journal: Br J Pharmacol Date: 2000-01 Impact factor: 8.739
Authors: Joris C Verster; Edmund R Volkerts; Armand W A A van Oosterwijck; Mounir Aarab; Saskia I R Bijtjes; A Marit De Weert; Erik J E Eijken; Marinus N Verbaten Journal: J Allergy Clin Immunol Date: 2003-03 Impact factor: 10.793
Authors: Silke Conen; Eef L Theunissen; Annemiek Vermeeren; Peter van Ruitenbeek; Peter Stiers; Mitul A Mehta; Stefan W Toennes; Johannes G Ramaekers Journal: Psychopharmacology (Berl) Date: 2013-04-07 Impact factor: 4.530
Authors: N N J J M van der Sluiszen; A Vermeeren; S Jongen; E L Theunissen; A C M van Oers; C J Van Leeuwen; A Maret; C Desforges; A Delarue; J G Ramaekers Journal: Psychopharmacology (Berl) Date: 2016-08-04 Impact factor: 4.530
Authors: Annemiek Vermeeren; Eva Vets; Eric F P M Vuurman; Anita C M Van Oers; Stefan Jongen; Tine Laethem; Ingeborg Heirman; An Bautmans; John Palcza; Xiadong Li; Matthew D Troyer; Rebecca Wrishko; Jacqueline McCrea; Hong Sun Journal: Psychopharmacology (Berl) Date: 2016-07-16 Impact factor: 4.530
Authors: Nick N J J M van der Sluiszen; Annemiek Vermeeren; Joke H van Dijken; Aurora J A E van de Loo; Janet L Veldstra; Dick de Waard; Joris C Verster; Karel A Brookhuis; Johannes G Ramaekers Journal: Hum Psychopharmacol Date: 2020-10-01 Impact factor: 1.672